| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kyowa Kirin Co. Ltd. | OTL-203 - (HURCULES) | Mucopolysaccharidosis type I (MPS-I) | Phase 3 | Enrollment Initiation | Intravenous infusion | Genetic Disorder |
| Kyverna Therapeutics Inc. | Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-8) | Stiff-person syndrome (SPS) | BLA Filing | Data Released | Intravenous | Neurology |
| Kyverna Therapeutics Inc. | Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-8) | Stiff-person syndrome (SPS) | BLA Filing | Data Released | Intravenous | Neurology |
| Kyverna Therapeutics Inc. | Miv-cel (mivocabtagene autoleucel, KYV-101) - (KYSA-6) | Myasthenia gravis (MG) | Phase 2 | Data Released | Intravenous | Neurology |
| Kyverna Therapeutics Inc. | KYV-101 | Non-relapsing and Progressive Forms of Multiple Sclerosis | Phase 2 | Ongoing | Intravenous | Neurology |
| LakeShore Biopharma Co. Ltd Ord | PIKA Rabies Vaccine | Rabies | BLA Filing | Data Released | Intramuscular | N/A |
| LakeShore Biopharma Co. Ltd Ord | PIKA Recombinant COVID-19 Vaccine | COVID-19 | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
| Lantern Pharma Inc. | LP-300 - (Harmonic) | Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |